胰腺癌患者治疗前血小板计数作为预后因素的系统评价与Meta分析
Pretreatment platelet count as a prognostic factor in patients with pancreatic cancer: a systematic review and meta-analysis.
作者信息
Chen Sheng, Na Ning, Jian Zhixiang
机构信息
Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences.
Department of Kidney Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
出版信息
Onco Targets Ther. 2017 Dec 21;11:59-65. doi: 10.2147/OTT.S147715. eCollection 2018.
BACKGROUND
The relationship between platelet counts and pancreatic cancer as a prognostic factor has been reported in many studies. We aimed to evaluate the prognostic value of platelet counts in predicting the prognosis of pancreatic cancer patients.
METHODS
We searched PubMed, Medline, EMBASE, and Google Scholar for eligible studies up to May 2017. Information about the characteristics of the study and relevant outcomes was extracted. A meta-analysis was performed to analyze the prognostic value of platelet counts using the hazard ratio (HR) and 95% confidence intervals (CIs).
RESULTS
A total of 1,756 patients in 13 retrospective studies were included. The pooled HR of 1.51 (95% CI: 1.20-1.90, <0.001) showed that patients with elevated platelet counts were expected to have poor overall survival after treatment. Subgroup analysis showed that prognostic value of platelet levels was stronger in patients who received surgical resection (HR =1.60, 95% CI: 1.09-2.34, =0.02), followed by patients who received palliative therapy (HR =1.46, 95% CI: 1.03-2.06, =0.03).
CONCLUSION
Platelet counts could be a useful prognostic marker for pancreatic cancer. Patients with high platelet counts are expected to have poor survival.
背景
许多研究报道了血小板计数与胰腺癌作为预后因素之间的关系。我们旨在评估血小板计数在预测胰腺癌患者预后方面的预后价值。
方法
我们检索了截至2017年5月的PubMed、Medline、EMBASE和谷歌学术，以查找符合条件的研究。提取了有关研究特征和相关结果的信息。使用风险比（HR）和95%置信区间（CI）进行荟萃分析，以分析血小板计数的预后价值。
结果
13项回顾性研究共纳入1756例患者。汇总的HR为1.51（95%CI：1.20-1.90，<0.001），表明血小板计数升高的患者治疗后总体生存预后较差。亚组分析表明，血小板水平的预后价值在接受手术切除的患者中更强（HR=1.60，95%CI：1.09-2.34，=0.02），其次是接受姑息治疗的患者（HR=1.46，95%CI：1.03-2.06，=0.03）。
结论
血小板计数可能是胰腺癌有用的预后标志物。血小板计数高的患者生存预后较差。
Zotero 插件